Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Brain Metastases from Breast Cancer, NSCLC, or Melanoma
NCT02308020Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of abemaciclib in breast cancer, non-small cell lung cancer (NSCLC), melanoma, sponsored by Eli Lilly and Company. Started Apr 2015; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT02308020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308020.